- Report
- February 2020
- 163 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- June 2019
- 53 Pages
Global
From €6762EUR$6,995USD£5,812GBP
- Drug Pipelines
- November 2020
- 816 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- February 2024
- 103 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- October 2023
- 89 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- August 2023
- 111 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- September 2022
- 432 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- May 2022
- 290 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Report
- May 2022
- 40 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- May 2022
- 47 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- February 2024
- 180 Pages
Global
From €5316EUR$5,499USD£4,569GBP
- Report
- April 2023
- 147 Pages
Global
From €5799EUR$5,999USD£4,985GBP
The Lupus Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for autoimmune diseases such as lupus. Lupus is a chronic, autoimmune disorder that can cause inflammation, pain, and tissue damage in various parts of the body. Lupus drugs are used to reduce inflammation, suppress the immune system, and reduce the risk of organ damage. These drugs are typically prescribed in combination with other treatments such as lifestyle changes, physical therapy, and other medications.
The Lupus Drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Companies in the market include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Roche. Show Less Read more
